Search Results for "Xeljanz"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Xeljanz. Results 11 to 17 of 17 total matches.
See also: tofacitinib
Risankizumab (Skyrizi) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
(Velsipity) are alternatives. The oral Janus
kinase (JAK) inhibitors tofacitinib (Xeljanz, and others ...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzza (Skyrizi – Abbvie), previously
approved by the FDA for treatment of Crohn's disease
(CD), has now been approved for treatment of
moderately to severely active ulcerative colitis (UC)
in adults. Risankizumab is the first IL-23 antagonist
to be approved for treatment of both CD and UC. It is
also approved for treatment of plaque psoriasis and
psoriatic arthritis.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):182-4 doi:10.58347/tml.2024.1715d | Show Introduction Hide Introduction
Guselkumab (Tremfya) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Mar 17, 2025 (Issue 1724)
(JAK) inhibitors such as tofacitinib (Xeljanz, and
others) and upadacitinib (Rinvoq) are FDA-approved ...
The interleukin (IL)-23 antagonist guselkumab
(Tremfya – Janssen Biotech) has now been approved
by the FDA for treatment of moderately to severely active ulcerative colitis (UC) in adults; it was
approved earlier for treatment of plaque psoriasis
and psoriatic arthritis. Guselkumab is the third IL-23
antagonist to be approved in the US for treatment of
UC; risankizumab (Skyrizi) and mirikizumab (Omvoh)
were approved earlier.
Med Lett Drugs Ther. 2025 Mar 17;67(1724):46-8 doi:10.58347/tml.2025.1724d | Show Introduction Hide Introduction
Expanded Table: Some Drugs for Inflammatory Bowel Disease (online only)
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
not tolerate a TNF inhibitor
19,734.60
Janus Kinase (JAK) Inhibitor
Tofacitinib2 – Xeljanz
(Pfizer ...
View the Table: Some Drugs for Inflammatory Bowel Disease
Med Lett Drugs Ther. 2023 Jul 10;65(1680):e115-9 doi:10.58347/tml.2023.1680d | Show Introduction Hide Introduction
Drugs for Rheumatoid Arthritis
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
Baricitinib – Olumiant (Lilly) 2 mg tabs 2 mg PO once/day 2378.40
Tofacitinib – Xeljanz (Pfizer) 5 mg tabs 5 ...
Rheumatoid arthritis (RA) is prevalent in 0.5% of
adults in the US; it is about 2.5 times more common
in women than in men. Guidelines for treatment
of RA from the American College of Rheumatology
were recently updated. The goal of treatment is to
minimize disease activity and prevent irreversible
joint damage.
Drugs for Inflammatory Bowel Disease
The Medical Letter on Drugs and Therapeutics • Jul 10, 2023 (Issue 1680)
have
occurred rarely.
JAK INHIBITORS — The oral Janus kinase (JAK)
inhibitors tofacitinib (Xeljanz ...
Ulcerative colitis (UC) and Crohn's disease (CD),
referred to collectively as inflammatory bowel disease
(IBD), are chronic immune-mediated inflammatory
conditions. Guidelines for treatment of UC and CD
have been updated in recent years
Med Lett Drugs Ther. 2023 Jul 10;65(1680):105-12 doi:10.58347/tml.2023.1680a | Show Introduction Hide Introduction
Ruxolitinib Cream (Opzelura) for Nonsegmental Vitiligo
The Medical Letter on Drugs and Therapeutics • Oct 03, 2022 (Issue 1660)
by the results of
a postmarketing safety trial with oral tofacitinib
(Xeljanz, and others) and were added ...
The 1.5% cream formulation of the Janus kinase
(JAK) inhibitor ruxolitinib (Opzelura – Incyte) has
been approved by the FDA for topical treatment of
nonsegmental vitiligo (NSV) in patients ≥12 years old.
Opzelura is the first product to be approved by the
FDA for this indication. It was previously approved for
treatment of atopic dermatitis.
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
by
the results of a postmarketing safety trial with oral
tofacitinib (Xeljanz, and others) and were added ...
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for treatment of
moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5 doi:10.58347/tml.2023.1673b | Show Introduction Hide Introduction